Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.99.
Syndax Pharmaceuticals Inc (SNDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 5,660,000 | $122,312,600 | +58% | 13.55% |
| 2. | VenBio Select Advisor Kurt Von Emster | 4,222,222 | $91,242,217 | +66% | 1.26% |
| 3. | Avidity Partners Management David Witzke And Michael Gregory | 3,950,000 | $85,359,500 | +41% | 3.11% |
| 4. | Eversept Partners Kamran Moghtaderi | 3,383,244 | $73,111,903 | +31% | 6.42% |
| 5. | Point72 Asset Management Steve Cohen | 2,834,499 | $61,253,523 | +36% | 0.14% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.46 | 500 | 15,666 | 2021-04-26 | Filing | ||
| $14.11 | 13,967 | 43,300 | 2021-04-22 | Filing | ||
| $8.00 | 12,500 | 43,900 | 2020-02-04 | Filing | ||
| $5.40 | 11,000 | 31,400 | 2019-10-10 | Filing | ||
| $7.29 | 7,200 | 20,400 | 2019-05-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.27 | 52,855 | 17,836 | 2023-08-09 | Filing | ||
| $20.45 | 24,000 | 48,000 | 2023-08-02 | Filing | ||
| $20.46 | 24,000 | 48,000 | 2023-08-02 | Filing | ||
| $20.46 | 35,000 | 48,000 | 2023-08-02 | Filing | ||
| $20.40 | 52,855 | 17,836 | 2023-07-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,585,221 | $163,916,627 | 0.03% | |
| 2. | 7,015,548 | $151,605,991 | 0% | |
| 3. | 5,016,224 | $108,400,601 | 0% | |
| 4. | 4,335,353 | $93,686,978 | 0% | |
| 5. | 1,664,306 | $35,965,653 | 0% |
News See All
12 Most Promising Cancer Stocks According to Analysts
In this piece, we will take a look at the 12 most promising cancer stocks according to analysts.
12 Most Promising Stocks to Buy According to Hedge Funds
In this article, we will take a look at the 12 most promising stocks to buy according to hedge funds.
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax Third Quarter 2023 Earnings Conference Call. Today's call is being recorded.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax Second Quarter 2023 Earnings Conference Call. Today's call is being recorded.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax First Quarter 2023 Earnings Conference Call. Today's call is being recorded.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2022 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter 2022 Conference Call. Today's call is being recorded.
10 Best Stocks to Buy According to Ari Zweiman’s 683 Capital Partners
In this article, we present the list of top 10 stock picks of Ari Zweiman’s 683 Capital Partners at the end of the second quarter.
Top 5 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying
Below we present the list of the top 5 healthcare stocks the experts at Sphera Global Healthcare Fund are buying.
Billionaire Hedge Funds
